Histamine, histamine receptors, and anti-histamines in the context of allergic responses
Abstract
Histamine is a bioactive amine which is considered a key player in the allergic response. Thus, histamine receptor blockers (antihistamines) play an important role in the treatment of a number atopic diseases such as allergic rhinitis, conjunctivitis, and acute and chronic forms of urticaria. Histamine is produced by immune cells but also by bacteria in the gut. Beyond its role in the acute allergic response, histamine exerts numerous effects by binding to its 4 pleiotropic G-protein coupled histamine receptors. Here, we describe the roles of these histamine receptors and antihistamines in the human system, clinical applications, side effects, and novel concepts for the usage of antihistamines with different specificity based on guidelines and recommendations.
Statement of novelty: This review provides an overview of histamine receptors and links it to clinical relevance of antagonizing their action in clinical routine.
Formats available
You can view the full content in the following formats:
REFERENCES
Affrime M., Gupta S., Banfield C., and Cohen A. 2002. A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin. Pharmacokinet. 41:13–19.
Akamine Y. and Miura M. 2018. An update on the clinical pharmacokinetics of fexofenadine enantiomers. Expert Opin. Drug Metab. Toxicol. 14(4):429–434.
Akamine Y., Yasui-Furukori N., and Uno T. 2019. Drug-drug interactions of P-gp substrates unrelated to CYP metabolism. Curr. Drug Metab. 20(2):124–129.
Anthes J.C., Gilchrest H., Richard C., Eckel S., Hesk D., West R.E. Jr., Williams S.M., Greenfeder S., Billah M., Kreutner W., and Egan R.E. 2002. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor. Eur. J. Pharmacol. 449:229–237.
Antonijoan R., Coimbra J., García-Gea C., Puntes M., Gich I., Campo C., Valiente R., and Labeaga L. 2017. Comparative efficacy of bilastine, desloratadine and rupatadine in the suppression of wheal and flare response induced by intradermal histamine in healthy volunteers. Curr. Med. Res. Opin. 33(1):129–136.
Bakker R.A., Wieland K., Timmerman H., and Leurs R. 2000. Constitutive activity of the histamine H1 receptor reveals inverse agonism of histamine H1 receptor antagonists. Eur. J. Pharmacol. 387(1):R5–R7.
Baltes E., Coupez R., Giezek H., Voss G., Meyerhoff C., and Benedetti M.S. 2001. Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. Fundam. Clin. Pharmacol. 15(4):269–277.
Barbanoj M.J., García-Gea C., Morte A., Izquierdo I., Pérez I., and Jané F. 2004. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology. 50(4):311–321.
Barnes P.J. 1991. Histamine receptors in the lung. Agents Actions Suppl. 33:103–122.
Birdsall N.J.M. 1991. Cloning and structure-function of the H2 histamine receptor. Trends Pharmacol. Sci. 12(1):9–10.
Bockaert J. and Pin J.P. 1999. Molecular tinkering of G protein-coupled receptors: An evolutionary success. EMBO J. 18(7):1723–1729.
Boobis A., Watelet J.B., Whomsley R., Benedetti M.S., Demoly P., and Tipton K. 2009. Drug interactions. Drug Metab. Rev. 41(3):486–527.
Bousquet J., van Cauwenberge P., and Khaltaev N. 2001. Allergic Rhinitis and its Impact on Asthma. J. Allergy Clin. Immunol. 108(5 Suppl.):S147–S334.
Bousquet J., Khaltaev N., Cruz A.A., Denburg J., Fokkens W.J., Togias A., Zuberbier T., Baena-Cagnani C.E., Canonica G.W., van Weel C., Agache I., Aït-Khaled N., Bachert C., Blaiss M.S., Bonini S., Boulet L.P., Bousquet P.J., Camargos P., Carlsen K.H., Chen Y., Custovic A., Dahl R., Demoly P., Douagui H., Durham S.R., van Wijk R.G., Kalayci O., Kaliner M.A., Kim Y.Y., Kowalski M.L., Kuna P., Le L.T., Lemiere C., Li J., Lockey R.F., Mavale-Manuel S., Meltzer E.O., Mohammad Y., Mullol J., Naclerio R., O’Hehir R.E., Ohta K., Ouedraogo S., Palkonen S., Papadopoulos N., Passalacqua G., Pawankar R., Popov T.A., Rabe K.F., Rosado-Pinto J., Scadding G.K., Simons F.E., Toskala E., Valovirta E., van Cauwenberge P., Wang D.Y., Wickman M., Yawn B.P., Yorgancioglu A., Yusuf O.M., Zar H., Annesi-Maesano I., Bateman E.D., Ben Kheder A., Boakye D.A., Bouchard J., Burney P., Busse W.W., Chan-Yeung M., Chavannes N.H., Chuchalin A., Dolen W.K., Emuzyte R., Grouse L., Humbert M., Jackson C., Johnston S.L., Keith P.K., Kemp J.P., Klossek J.M., Larenas-Linnemann D., Lipworth B., Malo J.L., Marshall G.D., Naspitz C., Nekam K., Niggemann B., Nizankowska-Mogilnicka E., Okamoto Y., Orru M.P., Potter P., Price D., Stoloff S.W., Vandenplas O., Viegi G., and Williams D. 2008. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008. Allergy. 63(Suppl. 86):8–160.
Brożek J.L., Bousquet J., Agache I., Agarwal A., Bachert C., Bosnic-Anticevich S., Brignardello-Petersen R., Canonica G.W., Casale T., Chavannes N.H., Correia de Sousa J., Cruz A.A., Cuello-Garcia C.A., Demoly P., Dykewicz M., Etxeandia-Ikobaltzeta I., Florez I.D., Fokkens W., Fonseca J., Hellings P.W., Klimek L., Kowalski S., Kuna P., Laisaar K.T., Larenas-Linnemann D.E., Lødrup Carlsen K.C., Manning P.J., Meltzer E., Mullol J., Muraro A., O’Hehir R., Ohta K., Panzner P., Papadopoulos N., Park H.S., Passalacqua G., Pawankar R., Price D., Riva J.J., Roldán Y., Ryan D., Sadeghirad B., Samolinski B., Schmid-Grendelmeier P., Sheikh A., Togias A., Valero A., Valiulis A., Valovirta E., Ventresca M., Wallace D., Waserman S., Wickman M., Wiercioch W., Yepes-Nuñez J.J., Zhang L., Zhang Y., Zidarn M., Zuberbier T., and Schünemann H.J. 2017. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. J. Allergy Clin. Immunol. 140(4):950–958.
Burgaud J.L. and Oudart N. 1993. Bronchodilatation of guinea-pig perfused bronchioles induced by the H3-receptor for histamine: Role of epithelium. Br. J. Pharmacol. 109(4):960–966.
Chen C., Hanson E., Watson J.W., and Lee J.S. 2003. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab. Dispos. 31(3):312–318.
Church M.K. 2011. Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans. Inflamm. Res. 60(12):1107–1112.
Church M.K., Maurer M., Simons F.E.R., Bindslev-Jensen C., van Cauwenberge P., Bousquet J., Holgate S.T., and Zuberbier T. 2010. Risk of first-generation H1-antihistamines: A GA2LEN position paper. Allergy. 65(4):459–466.
Cogé F., Guénin S.P., Rique H., Boutin J.A., and Galizzi J.P. 2001. Structure and expression of the human histamine H4-receptor gene. Biochem. Biophys. Res. Commun. 284(2):301–309.
Dávila I., del Cuvillo A., Mullol J., Jáuregui I., Bartra J., Ferrer M., Montoro J., Sastre J., and Valero A. 2013. Use of second generation H1 antihistamines in special situations. J. Investig. Allergol. Clin. Immunol. 23(Suppl. 1):1–16.
De Bruin M.L., van Puijenbroek E.P., Egberts A.C.G., Hoes A.W., and Leufkens H.G.M. 2002. Non-sedating antihistamine drugs and cardiac arrhythmias—Biased risk estimates from spontaneous reporting systems? Br. J. Clin. Pharmacol. 53(4):370–374.
del Cuvillo A., Mullol J., Bartra J., Dávila I., Jáuregui I., Montoro J., Sastre J., and Valero A.L. 2006. Comparative pharmacology of the H1 antihistamines. J. Investig. Allergol. Clin. Immunol. 16(Suppl. 1):3–12.
Dressler C., Rosumeck S., Werner R.N., Magerl M., Metz M., Maurer M., Nast A., and Zuberbier T. 2018. Executive summary of the methods report for ‘The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update’. Allergy. 73(5):1145–1146.
Ferstl R., Frei R., Barcik W., Schiavi E., Wanke K., Ziegler M., Rodriguez-Perez N., Groeger D., Konieczna P., Zeiter S., Nehrbass D., Lauener R., Akdis C.A., and O’Mahony L. 2017. Histamine receptor 2 modifies iNKT cell activity within the inflamed lung. Allergy. 72(12):1925–1935.
Fité-Mora R. 2009. Torsade de pointes relacionadas con el uso de rupatadina. Rev. Esp. Cardiol. 62(3):330–331; author reply 332.
García-Gálvez A.-M., Escamilla-Sanchez J., Flores-Maldonado C., Contreras R.-G., Arias J.-M., and Arias-Montano J.-A. 2018. Differential homologous desensitization of the human histamine H3 receptors of 445 and 365 amino acids expressed in CHO-K1 cells. Neurochem. Int. 112:114–123.
Greisner W.A. 2004. Onset of action for the relief of allergic rhinitis symptoms with second-generation antihistamines. Allergy Asthma Proc. 25(2):81–83.
Grimfeld A., Holgate S.T., Canonica G.W., Bonini S., Borres M.P., Adam D., Canseco Gonzalez C., Lobaton P., Patel P., Szczeklik A., Danzig M.R., Roman I., Bismut H., and Czarlewski W. 2004. Prophylactic management of children at risk for recurrent upper respiratory infections: The Preventia I Study. Clin. Exp. Allergy. 34(11):1665–1672.
Horak F., Zieglmayer P., Zieglmayer R., and Lemell P. 2010. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm. Res. 59(5):391–398.
Horsmans Y., Desager J.P., Hulhoven R., and Harvengt C. 1993. Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease. J. Clin. Pharmacol. 33(10):929–932.
Ishikawa M., Watanabe T., Kudo T., Yokoyama F., Yamauchi M., Kato K., Kakui N., and Sato Y. 2010. Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain. J. Med. Chem. 53(17):6445–6456.
Jablonowski J.A., Grice C.A., Chai W., Dvorak C.A., Venable J.D., Kwok A.K., Ly K.S., Wei J., Baker S.M., Desai P.J., Jiang W., Wilson S.J., Thurmond R.L., Karlsson L., Edwards J.P., Lovenberg T.W., and Carruthers N.I. 2003. The first potent and selective non-imidazole human histamine H4 receptor antagonists. J. Med. Chem. 46(19):3957–3960.
Juniper E.F., Howland W.C., Roberts N.B., Thompson A.K., and King D.R. 1998. Measuring quality of life in children with rhinoconjunctivitis. J. Allergy Clin. Immunol. 101(2 Pt 1):163–170.
Jutel M., Watanabe T., Klunker S., Akdis M., Thomet O.A., Malolepszy J., Zak-Nejmark T., Koga R., Kobayashi T., Blaser K., and Akdis C.A. 2001. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature. 413(6854):420–425.
Kaliner M.A. 2002. H1-antihistamines in the elderly. Clin. Allergy Immunol. 17:465–481.
Kanamitsu K., Nozaki Y., Nagaya Y., Sugiyama Y., and Kusuhara H. 2017. Corrigendum to “Quantitative prediction of histamine H1 receptor occupancy by the sedative and non-sedative antagonists in the human central nervous system based on systemic exposure and preclinical data” [Drug Metab Pharmacokinet 32 (2017) 135–144]. Drug Metab. Pharmacokinet. 32(4):228.
Kar S., Krishnan A., Preetha K., and Mohankar A. 2012. A review of antihistamines used during pregnancy. J. Pharmacol. Pharmacother. 3(2):105–108.
Kay G.G. and Quig M.E. 2001. Impact of sedating antihistamines on safety and productivity. Allergy Asthma Proc. 22(5):281–283.
Kiss R. and Keseru G.M. 2014. Novel histamine H4 receptor ligands and their potential therapeutic applications: An update. Expert Opin. Ther. Pat. 24(11):1185–1197.
Klimek L. 2009. Levocetirizine: From scientific evidence to a potent modern-day treatment of today’s allergic patients. Drugs Today. 45(3):213–225.
Köchling H., Schaper K., Wilzopolski J., Gutzmer R., Werfel T., Bäumer W., Kietzmann M., and Rossbach K. 2017. Combined treatment with H1 and H4 receptor antagonists reduces inflammation in a mouse model of atopic dermatitis. J. Dermatol. Sci. 87(2):130–137.
Kollmeier A., Francke K., Chen B., Dunford P.J., Greenspan A.J., Xia Y., Xu X.L., Zhou B., and Thurmond R.L. 2014. The histamine H4 receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects. J. Pharmacol. Exp. Ther. 350(1):181–187.
La Rosa M., Lionetti E., Reibaldi M., Russo A., Longo A., Leonardi S., Tomarchio S., Avitabile T., and Reibaldi A. 2013. Allergic conjunctivitis: A comprehensive review of the literature. Ital. J. Pediatr. 39(1):18.
Ling P., Ngo K., Nguyen S., Thurmond R.L., Edwards J.P., Karlsson L., and Fung-Leung W.-P. 2004. Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br. J. Pharmacol. 142(1):161–171.
Liu C., Wilson S.J., Kuei C., and Lovenberg T.W. 2001. Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. J. Pharmacol. Exp. Ther. 299(1):121–130.
Matsushita A., Seike M., Okawa H., Kadawaki Y., and Ohtsu H. 2012. Advantages of histamine H4 receptor antagonist usage with H1 receptor antagonist for the treatment of murine allergic contact dermatitis. Exp. Dermatol. 21(9):714–715.
McDonald K., Trick L., and Boyle J. 2008. Sedation and antihistamines: An update. Review of inter-drug differences using proportional impairment ratios. Hum. Psychopharmacol. 23(7):555–570.
Miyano K., Matsushita S., Tsuchida T., and Nakamura K. 2016. Inhibitory effect of a histamine 4 receptor antagonist on CCL17 and CCL22 production by monocyte-derived Langerhans cells in patients with atopic dermatitis. J. Dermatol. 43(9):1024–1029.
Muraro A., Werfel T., Hoffmann-Sommergruber K., Roberts G., Beyer K., Bindslev-Jensen C., Cardona V., Dubois A., duToit G., Eigenmann P., Fernandez Rivas M., Halken S., Hickstein L., Høst A., Knol E., Lack G., Marchisotto M.J., Niggemann B., Nwaru B.I., Papadopoulos N.G., Poulsen L.K., Santos A.F., Skypala I., Schoepfer A., Van Ree R., Venter C., Worm M., Vlieg-Boerstra B., Panesar S., de Silva D., Soares-Weiser K., Sheikh A., Ballmer-Weber B.K., Nilsson C., de Jong N.W., Akdis C.A., and EAACI Food Allergy and Anaphylaxis Guidelines Group. 2014. EAACI food allergy and anaphylaxis guidelines: Diagnosis and management of food allergy. Allergy. 69(8):1008–1025.
Muraro A., Lemanske R.F. Jr., Castells M., Torres M.J., Khan D., Simon H.U., Bindslev-Jensen C., Burks W., Poulsen L.K., Sampson H.A., Worm M., and Nadeau K.C. 2017. Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy. 72(7):1006–1021.
Murata Y., Song M., Kikuchi H., Hisamichi K., Xu X.L., Greenspan A., Kato M., Chiou C.F., Kato T., Guzzo C., Thurmond R.L., Ohtsuki M., and Furue M. 2015. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. J. Dermatol. 42(2):129–139.
Nakamura T., Itadani H., Hidaka Y., Ohta M., and Tanaka K. 2000. Molecular cloning and characterization of a new human histamine receptor, HH4R. Biochem. Biophys. Res. Commun. 279(2):615–620.
Nieto-Alamilla G., Márquez-Gómez R., García-Gálvez A.M., Morales-Figueroa G.E., and Arias-Montaño J.A. 2016. The histamine H3 receptor: Structure, pharmacology, and function. Mol. Pharmacol. 90(5):649–673.
Novak N., Mete N., Bussmann C., Maintz L., Bieber T., Akdis M., Zumkehr J., Jutel M., and Akdis C. 2012. Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2. J. Allergy Clin. Immunol. 130(5):1153–1158.e2.
Ohsawa Y. and Hirasawa N. 2012. The antagonism of histamine H1 and H4 receptors ameliorates chronic allergic dermatitis via anti-pruritic and anti-inflammatory effects in NC/Nga mice. Allergy. 67(8):1014–1022.
Pajno G.B., Fernandez-Rivas M., Arasi S., Roberts G., Akdis C.A., Alvaro-Lozano M., Beyer K., Bindslev-Jensen C., Burks W., Ebisawa M., Eigenmann P., Knol E., Nadeau K.C., Poulsen L.K., van Ree R., Santos A.F., du Toit G., Dhami S., Nurmatov U., Boloh Y., Makela M., O’Mahony L., Papadopoulos N., Sackesen C., Agache I., Angier E., Halken S., Jutel M., Lau S., Pfaar O., Ryan D., Sturm G., Varga E.M., van Wijk R.G., Sheikh A., Muraro A., and EAACI Allergen Immunotherapy Guidelines Group. 2018. EAACI guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy. 73(4):799–815.
Pedersen L., Nørgaard M., Skriver M.V., Olsen J., and Sørensen H.T. 2006. Prenatal exposure to loratadine in children with hypospadias: A nested case-control study within the Danish National Birth Cohort. Am. J. Ther. 13(4):320–324.
Polli J.W., Baughman T.M., Humphreys J.E., Jordan K.H., Mote A.L., Salisbury J.A., Tippin T.K., and Serabjit-Singh C.J. 2003. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. J. Pharm. Sci. 92(10):2082–2089.
Potter P., Maspero J.F., Vermeulen J., Barkai L., Németh I., Baillieau R.A., Garde J.M., Giralt J., Doménech A., Izquierdo I., and Nieto A. 2013. Rupatadine oral solution in children with persistent allergic rhinitis: A randomized, double-blind, placebo-controlled study. Pediatr. Allergy Immunol. 24(2):144–150.
Potter P., Mitha E., Barkai L., Mezei G., Santamaría E., Izquierdo I., and Maurer M. 2016. Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2–11 years. Pediatr. Allergy Immunol. 27(1):55–61.
Santamaría E., Izquierdo I., Valle M., Vermeulen J.H., and Potter P. 2018. Rupatadine oral solution for 2–5-year-old children with allergic rhinitis: A safety, open-label, prospective study. J. Asthma Allergy. 11:225–231.
Scharf M. and Berkowitz D. 2007. Effects of desloratadine and alcohol coadministration on psychomotor performance. Curr. Med. Res. Opin. 23(2):313–321.
Schwarz E.B., Moretti M.E., Nayak S., and Koren G. 2008. Risk of hypospadias in offspring of women using loratadine during pregnancy: A systematic review and meta-analysis. Drug Saf. 31(9):775–788.
Shamizadeh S., Brockow K., and Ring J. 2014. Rupatadine: Efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects. Allergo J. Int. 23:87–95.
Shamsi Z. and Hindmarch I. 2000. Sedation and antihistamines: A review of inter-drug differences using proportional impairment ratios. Hum. Psychopharmacol. 15(S1):S3–S30.
Shimizu M., Uno T., Sugawara K., and Tateishi T. 2006. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br. J. Clin. Pharmacol. 61(5):538–544.
Simons F.E.R. 1999. Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. J. Allergy Clin. Immunol. 104(2 Pt 1):433–440.
Simons F.E.R. 2004. Advances in H1-antihistamines. N. Engl. J. Med. 351(21):2203–2217.
Simons, F.E.R., and Akdis, A.C. 2013. Histamine and H1-antihistamines. In Middleton’s allergy: Principles and practice. Edited by N.F. Adkinson, Jr., B.S. Bochner, W.W. Busse, S.T. Holgate, R.F. Lemanske, Jr., and F.E.R. Simons. St. Louis, MO, USA: Mosby. pp. 1503–1533.
Simons F.E.R. and Early Prevention of Asthma in Atopic Children (EPAAC) Study Group. 2007. Safety of levocetirizine treatment in young atopic children: An 18-month study. Pediatr. Allergy Immunol. 18(6):535–542.
Simons F.E.R. and Simons K.J. 1999. Clinical pharmacology of new histamine H1 receptor antagonists. Clin. Pharmacokinet. 36(5):329–352.
Simons F.E.R., Silas P., Portnoy J.M., Catuogno J., Chapman D., and Olufade A.O. 2003. Safety of cetirizine in infants 6 to 11 months of age: A randomized, double-blind, placebo-controlled study. J. Allergy Clin. Immunol. 111(6):1244–1248.
Simons F.E.R., Ardusso L.R., Bilò M.B., Cardona V., Ebisawa M., El-Gamal Y.M., Lieberman P., Lockey R.F., Muraro A., Roberts G., Sanchez-Borges M., Sheikh A., Shek L.P., Wallace D.V., and Worm M. 2014. International consensus on (ICON) anaphylaxis. World Allergy Organ. J. 7(1):9.
Smolinska S., Groeger D., Perez N.R., Schiavi E., Ferstl R., Frei R., Konieczna P., Akdis C.A., Jutel M., and O’Mahony L. 2016. Histamine receptor 2 is required to suppress innate immune responses to bacterial ligands in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 22(7):1575–1586.
Täubel J., Ferber G., Fernandes S., Santamaría E., and Izquierdo I. 2018. Cardiac safety of rupatadine in a single-ascending-dose and multiple-ascending-dose study in healthy Japanese subjects, using intensive electrocardiogram assessments-comparison with the previous white Caucasian thorough QT study. Clin. Pharmacol. Drug Dev. 7(1):67–76.
Tenn M.W., Steacy L.M., Ng C.C., and Ellis A.K. 2018. Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the environmental exposure unit: A post hoc analysis of total symptom score. Allergy Asthma Clin. Immunol. 14(1):5.
Thurmond R.L. 2015. The histamine H4 receptor: From orphan to the clinic. Front. Pharmacol. 6:65.
Tichenor M.S., Thurmond R.L., Venable J.D., and Savall B.M. 2015. Functional profiling of 2-aminopyrimidine histamine H4 receptor modulators. J. Med. Chem. 58(18):7119–7127.
Tillement J.-P. 2000. The advantages for an H1 antihistamine of a low volume of distribution. Allergy. 55(Suppl. 60):17–21.
Timmerman H. 1992. Cloning of the H1 histamine receptor. Trends Pharmacol. Sci. 13(1):6–7.
Wood S.G., John B.A., Chasseaud L.F., Yeh J., and Chung M. 1987. The metabolism and pharmacokinetics of 14C-cetirizine in humans. Ann. Allergy. 59(6 Pt 2):31–34.
Woosley R.L. 1996. Cardiac actions of antihistamines. Annu. Rev. Pharmacol. Toxicol. 36(1):233–252.
Wu K.G., Li T.H., Wang T.Y., Hsu C.L., and Chen C.J. 2012. A comparative study of loratadine syrup and cyproheptadine HCL solution for treating perennial allergic rhinitis in Taiwanese children aged 2–12 years. Int. J. Immunopathol. Pharmacol. 25(1):231–237.
Yamashita M., Fukui H., Sugama K., Horio Y., Ito S., Mizuguchi H., and Wada H. 1991. Expression cloning of a cDNA encoding the bovine histamine H1 receptor. Proc. Natl. Acad. Sci. USA. 88(24):11515–11519.
Yap Y.G. and Camm A.J. 2002. Potential cardiac toxicity of H1-antihistamines. Clin. Allergy Immunol. 17:389–419.
Information & Authors
Information
Published In
LymphoSign Journal
Volume 6 • Number 2 • June 2019
Pages: 35 - 51
History
Received: 11 December 2018
Accepted: 8 January 2019
Accepted manuscript online: 24 April 2019
Copyright
© 2019.
Authors
Funding Information
This review did not receive any specific grant or funding.
Metrics & Citations
Metrics
Other Metrics
Citations
Cite As
AmarillaMandola, AsakoNozawa, and ThomasEiwegger. 2019. Histamine, histamine receptors, and anti-histamines in the context of allergic responses. LymphoSign Journal.
6(2): 35-51. https://doi.org/10.14785/lymphosign-2018-0016
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
There are no citations for this item
View Options
Get Access
Login options
Check if you access through your login credentials or your institution to get full access on this article.
